zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Provisional establishment of quality control strains for antimicrobial susceptibility testing of Mycoplasma hyorhinis (2020)

    Art
    Poster
    Autoren
    Käbisch, Lisa (WE 6)
    Schink, Anne-Kathrin (WE 7)
    Schwarz, Stefan (WE 7)
    Kongress
    Zoonoses 2020 - International Symposium on Zoonoses Research
    online, 15. – 16.10.2020
    Quelle
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://evis.events/event/119/contributions/2472/contribution.pdf
    Kontakt
    Institut für Immunologie

    Robert-von-Ostertag-Str. 7-13
    14163 Berlin
    +49 30 838 51834
    immunologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Background and objectives:
    Quality control (QC) strains are important to ensure the functionality of a test system. The Clinical and Laboratory Standards Institute (CLSI) has approved several QC strains for antimicrobial susceptibility testing (AST) of numerous bacteria, but not yet for Mycoplasma hyorhinis. The aim of this study was to investigate CLSI-approved QC strains for their suitability in AST of M. hyorhinis.

    Material and methods:
    Two QC strains were tested using commercial microtiter plates that contain 18 antimicrobial agents and Mycoplasma-specific Friis medium. Enterococcus faecalis ATCC® 29212 and Staphylococcus aureus ATCC® 29213 were incubated for 24 h, 48 h and 72 h at 35 ℃ ± 2 ℃ in ambient air. The prolonged incubation time relates to the incubation time suitable for M. hyorhinis. The strains were tested at least 11 times at independent occasions.

    Results:
    In the Friis medium, the MICs of the following strain-antimicrobial agent combinations were mainly within the acceptable ranges: E. faecalis ATCC® 29212 (gentamicin, streptomycin, enrofloxacin, florfenicol, erythromycin, tilmicosin, tulathromycin, tylosin, doxycycline) and S. aureus ATCC® 29213 (neomycin,
    ciprofloxacin, marbofloxacin, clindamycin, pirlimycin, linezolid, tiamulin, quinupristin-dalfopristin, tetracycline).

    Conclusion:
    As long as no M. hyorhinis QC strain is approved, we propose the provisional use of the two ATCC® strains 29212 and 29213 as QC strains for M. hyorhinis AST in Friis medium.